Cambridge Healthtech Institute’s Inaugural

Applying 3D Models

Bridging the Gap Between 2D Cell Culture and Animal Models

JUNE 19-20, 2019

Finding physiological relevant models for complex and heterogeneous diseases has never been more important. Cells grown in a monolayer are useful to explore diseases but lack tissue-level structure that is key to mimicking the human body. Animal models have fundamental species differences that decrease their predictive abilities. Join us at Cambridge Healthtech Institute’s Inaugural Applying 3D Models conference as leaders in the field discuss the use of spheroids, tumoroids, organoids, organs-on-a-chip and other microfluidic strategies for drug discovery across several therapeutic areas.

Final Agenda

Arrive early to attend Tuesday, June 18 - Wednesday, June 19

Applying 3D Models

Recommended Short Course

SC3A: Development of Micro Physiological Systems for Drug Screening


Wednesday, June 19

12:00 pm Registration Open

12:00 Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Transition to Plenary


2:20 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing


3:05 Chairperson’s Remarks

Jason Ekert, PhD, MBA, Head, Complex In Vitro Models, R&D Platform Technology & Science, GlaxoSmithKline

3:10 KEYNOTE PRESENTATION: Implementation of Multi-Dimensional Cellular Tumor Models with Increased Translational Relevance in Preclinical Oncology Drug Development

Jason Ekert, PhD, MBA, Head, Complex In Vitro Models, R&D Platform Technology & Science, GlaxoSmithKline

The current preclinical oncology drug discovery paradigm involves lengthy and costly optimization/lead discovery campaigns, often using cellular or in vivo tumor models with weak translational relevance that don’t closely resemble human solid tumors. I will highlight opportunities/challenges in implementing 3D solid tumor models. I will outline key components that should be considered when developing, validating, scaling and automating 3D solid tumor models that are more physiologically relevant.

3:40 Human Tumor Organoids as a Novel Model for Drug Discovery and Screening

Janica Wong, PhD, Senior Scientist, Discovery Oncology, Merck Research Labs

Stem cell-derived organoids are self-organizing three-dimensional (3D) structures generated in vitro recapitulating the cellular architecture and functions of the tumor, which may be a more relevant model to study cancer biology. 3D in vitro tumoroids were established from human tumor tissues. Tumoroids transplanted into humanized mice produced tumors that resembled primary human tumors, suggesting organoids are a useful model for predicting drug responses with potential for use in precision medicine.

4:10 Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac_HerveHervé Tiriac, PhD, Associate Project Scientist, Department of Surgery, UC San Diego

New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for pancreatic cancer patients. Combined genomic, transcriptomic, and therapeutic profiling of patient-derived organoids can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses and facilitate precision medicine for pancreatic cancer patients.

4:40 Sponsored Presentation (Opportunity Available)

5:10 Networking Reception in the Exhibit Hall with Poster Viewing

6:05 Close of Day

5:45 Dinner Short Course Registration

6:15 Dinner Short Course*

*Separate registration required.

Thursday, June 20

7:15 am Registration Open

7:15 Breakout Discussion Groups with Continental Breakfast


8:10 Chairperson’s Remarks

Louis Scampavia, PhD, Senior Scientific Director of HTS Chemistry and Technologies, Scripps Research

8:15 Ex Vivo Profiling of Response to PD-1 Blockade Using Organotypic Tumor Spheroids

Ivanova_ElenaElena Ivanova, PhD, Senior Scientist, Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute

We have developed an approach enabling ex vivo studies of anti-PD-1/PD-L1 and combination therapies using murine- and patient derived organotypic tumor spheroids (mDOTS/pDOTS) cultured in a novel 3D microfluidic system. We have demonstrated that the DOTS platform is feasible for image analysis, cytokine profiling, and RNA expression studies including single-cell RNAseq. This combination of techniques allows us to characterize dynamic, high-resolution profiles of checkpoint blockade response.

8:45 TANK-Binding Kinase 1 (TBK1) as a Cancer Immunotherapy Target

jenkins_RussellRussell W. Jenkins, MD, PhD, Assistant Professor, Department of Medicine, Center for Cancer Research, Massachusetts General Hospital

Innate resistance to PD-1 blockade remains a major challenge and strategies to overcome immune suppression and render the TME more permissive to T cell infiltration and function are under pre-clinical and clinical evaluation. TANK-binding kinase 1 (TBK1) is emerging as an attractive, novel cancer immunotherapy target to enhance response to anti-PD-1 therapies. Here, we describe tumor-intrinsic and tumor-extrinsic roles of TBK1 in modulating response to PD-1 blockade.

9:15 Microfluidic Assembly Of Hydrogel-Based Immunogenic Tumor Spheroids For Evaluation Of Anticancer Therapies And Biomarker Release

Konry_TaliTania (Tali) Konry, PhD, Assistant Professor, Department of Pharmaceutical Sciences, Northeastern University

This study describes the development of an integrated droplet microfluidics-based platform for high-throughput generation of immunogenic DLBCL spheroids. The spheroids consist of three cell types (cancer, fibroblast and lymphocytes) in a novel hydrogel combination of alginate and puramatrix, which promoted cell adhesion and aggregation. This system facilitates dynamic analysis of cellular interaction, proliferation and therapeutic efficacy via spatiotemporal monitoring and secretome profiling.

9:45 Sponsored Presentation (Opportunity Available)

10:15 Coffee Break in the Exhibit Hall with Poster Viewing


11:00 A PDX/Organoid Biobank of Advanced Prostate Cancer for Disease Modeling and Therapeutic Screening

kelly_kathleenKathleen Kelly, PhD, Lab Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute

Organoid cultures provide a technology to culture epithelial cancers that otherwise do not propagate in vitro. We have established a preclinical platform of PDX- and patient biopsy-derived metastatic castrate resistant prostate cancer (mCRPC) organoids that is experimentally facile for high throughput and mechanistic analysis. The genetic and phenotypic variability and stability of models, genetic manipulations, and the utility of such a platform for drug sensitivity determination will be discussed.

11:30 Enabling High Throughput Screening with Patient Derived 3D Cancer Spheroids/Organoids

Scampavia_LouisLouis Scampavia, PhD, Senior Scientific Director, Molecular Medicine Department, Scripps Research, Florida Campus

3D enabling technologies are now cost-effective and practical for generating cancer spheroids/organoids by combining the use of cell-repellent surfaces and magnetic bio-printing. The Scripps Research High Throughput Screening (HTS) center has adapted these breakthroughs for spheroid-based drug screening using patient-derived cancer cell lines in a 1536w format. Large-scale drug testing and reformulation/repurposing studies as well as novel drug discovery campaigns are now implemented using HTS automation in a cost-effective manner.

12:00 pm Cancer Models: Immune Checkpoint Blockade Therapies and Metastatic Disease

Kamm_RogerRoger D. Kamm, PhD, Green Distinguished Professor of Mechanical and Biological Engineering, Departments of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology

Microfluidic technologies for 3D culture have enabled more realistic models of cancer, both as disease models, and as platforms for drug screening or patient-targeted therapies. Two applications will be discussed. First, we explore the mechanisms by which circulating tumor cells home to the brain, transmigrate across the vascular endothelium, and initiate a metastatic tumor. Next, we demonstrate how microfluidics can be used to screen for effective patient-specific immunotherapies.

12:30 Sponsored Presentation (Opportunity Available)

1:00 Transition to Lunch

1:05 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:35 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing



2:20 Chairperson’s Remarks

Piotr Walczak, MD, PhD, Associate Professor, Radiology, Johns Hopkins University

2:25 A Perfused Human Blood–Brain Barrier On-A-Chip for High- Throughput Assessment of Barrier Function and Antibody Transport

Wevers_NienkeNienke Wevers, Scientist/PhD Candidate, Mimetas

We present a novel model of the human blood-brain barrier (BBB) in a high-throughput microfluidic system that allows parallel culture of 40 models at once. The model comprises brain endothelial cells, astrocytes, and pericytes and shows formation of a functional barrier. Passage of an antibody targeting the human transferrin receptor was markedly higher than penetration of a control antibody, indicating that this model could support further discovery and engineering of antibody BBB-shuttle technologies.

2:55 In Vitro and In Vivo Models to Evaluate P-gp and BCRP Activity in Regulating BBB Penetration

Xiao_GuanggingGuangqing Xiao, PhD, Associate Director, DMPK, Takeda

The presentation will give an overview of expression of Pgp and BCRP in BBB and BCSFB, species difference in expression, how Pgp and BCRP regulate BBB penetration, in vitro models to identify Pgp and BCRP substrates, and preclinical in vivo models to assess brain penetration, and how to use in vitro and in vivo models to identify compounds with good brain penetration.

3:25 Exploring the Utility of iPSC-Derived 3D Cortical Spheroids in the Detection of CNS Toxicity

Choi_ColinColin Choi, PhD, Scientist, Drug Safety Research and Evaluation, Takeda

Central Nervous System (CNS) toxicity is a common safety attrition for project failure during discovery and development phases due to low concordance rates between animal models and human, absence of clear biomarkers, and a lack of predictive assays. To address the challenge, we developed a CNS toxicity-detection strategy using a human iPSC-derived 3D microbrain model. Measuring viability and imaging-based functional endpoints, we conducted validation studies using compounds associated with neurodegeneration and seizure.

3:55 Linking Liver-on-a-Chip and Blood-Brain-Barrier-on-a-Chip for Toxicity Assessment

lelievre_sophieSophie Lelievre, DVM, PhD, LLM, Professor, Cancer Pharmacology, Purdue University College of Veterinary Medicine

One of the challenges to reproduce the function of tissues in vitro is the maintenance of differentiation. Essential aspects necessary for such endeavor involve good mechanical and chemical mimicry of the microenvironment. I will present examples of the management of the cellular microenvironment for liver and blood-brain-barrier tissue chips and discuss how on-a-chip devices maybe linked for the integrated study of the toxicity of drugs and other molecules.

4:25 Close of Conference

Arrive early to attend Tuesday, June 18 - Wednesday, June 19

Applying 3D Models

Recommended Short Course

SC3A: Development of Micro Physiological Systems for Drug Screening


* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Agenda,Sponsor updated
Agenda,Speaker updated
Speaker updated
Sponsor updated
Speaker,Sponsor updated
Agenda,Speaker,Sponsor updated